📰 Kumar Budur News
Kumar Budur News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Kumar Budur. Real-time updates on events, politics, business and more.
May 1, 2024
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q1 2024 Earnings Call Transcript April 30, 2024 Harmony Biosciences Holdings, Inc. beats earnings expectations. Reported EPS is $0.666, expectations were $0.64. Harmony Biosciences Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
April 30, 2024
HRMY earnings call for the period ending March 31, 2024.
April 5, 2024
The study will evaluate pitolisant for treating excessive daytime sleepiness and behavioral symptoms in patients with Prader-Willi syndrome.
April 3, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) has initiated its global Phase 3 registrational trial, the TEMPO study, to...
February 23, 2024
Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.74. Harmony Biosciences Holdings, Inc.
February 23, 2024
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2023 Earnings Call Transcript February 22, 2024 Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.45 EPS, expectations were $0.74. Harmony Biosciences Holdings, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). […]
February 22, 2024
Prader-Willi syndrome is a rare genetic disease characterized by severe hyperphagia that can lead to potentially life-threatening obesity.
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
February 22, 2024
HRMY earnings call for the period ending December 31, 2023.
February 20, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...